Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. trimmed its stake in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) by 21.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 43,102 shares of the company’s stock after selling 12,010 shares during the quarter. Raymond James Financial Services Advisors Inc. owned approximately 0.19% of Sol-Gel Technologies worth $48,000 at the end of the most recent quarter.

Separately, Yelin Lapidot Holdings Management Ltd. purchased a new position in Sol-Gel Technologies in the 3rd quarter worth about $374,000. 26.18% of the stock is currently owned by institutional investors and hedge funds.

Sol-Gel Technologies Trading Up 3.3 %

NASDAQ SLGL opened at $0.89 on Friday. Sol-Gel Technologies Ltd. has a 1 year low of $0.79 and a 1 year high of $4.05. The company has a market cap of $24.78 million, a PE ratio of -0.88 and a beta of 1.33. The stock’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $1.19.

Sol-Gel Technologies (NASDAQ:SLGL) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sol-Gel Technologies had a negative net margin of 1,331.01% and a negative return on equity of 61.52%. The firm had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.27 million. Research analysts forecast that Sol-Gel Technologies Ltd. will post -0.67 EPS for the current fiscal year.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.